Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for RedHill Biopharma (RDHL) over the last 4 years, with Jun 2025 value amounting to $500,000.

  • RedHill Biopharma's Total Non-Current Liabilities fell 31.51% to $500,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $500,000, marking a year-over-year decrease of 31.51%. This contributed to the annual value of $503,000 for FY2024, which is 49.45% down from last year.
  • Per RedHill Biopharma's latest filing, its Total Non-Current Liabilities stood at $500,000 for Q2 2025, which was down 0.60% from $503,000 recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Total Non-Current Liabilities ranged from a high of $94.9 million in Q2 2021 and a low of $500,000 during Q2 2025.
  • In the last 3 years, RedHill Biopharma's Total Non-Current Liabilities had a median value of $730,000 in 2024 and averaged $1.2 million.
  • Data for RedHill Biopharma's Total Non-Current Liabilities shows a maximum YoY slumped of 89.86% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Total Non-Current Liabilities stood at $90.8 million in 2021, then slumped by 89.19% to $9.8 million in 2022, then plummeted by 89.86% to $995,000 in 2023, then plummeted by 49.45% to $503,000 in 2024, then crashed by 31.51% to $500,000 in 2025.
  • Its Total Non-Current Liabilities was $500,000 in Q2 2025, compared to $503,000 in Q4 2024 and $730,000 in Q2 2024.